Preferred Label : Corticosterone methyloxidase type II deficiency;
CISMeF acronym : FHHA1B;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Aldosterone deficiency II; FHHA1B; Steroid 18-oxidase deficiency; Aldosterone deficiency due to deficiency of steroid 18-oxidase; 18-oxidase deficiency; Cmo II deficiency; Hyperreninemic hypoaldosteronism, familial, 1;
Description : CMO type II deficiency is an autosomal recessive disorder caused by a defect in the
final biochemical step of aldosterone biosynthesis, the 18-hydroxylation of 18-hydroxycorticosterone
(18-OHB) to aldosterone. This enzymatic defect results in decreased aldosterone and
salt-wasting associated with an increased serum ratio of 18-OHB to aldosterone. In
CMO II deficiency, aldosterone can be low or normal, but at the expense of increased
secretion of 18-OHB. These patients have a low ratio of corticosterone to 18-OHB (Portrat-Doyen
et al., 1998). The CYP11B2 gene product also catalyzes an earlier step in aldosterone
biosynthesis: the 18-hydroxylation of corticosterone to 18-OHB. A defect in that enzymatic
step results in CMO type I deficiency (204300), an allelic disorder with an overlapping
phenotype but distinct biochemical features. In CMO I deficiency, aldosterone is undetectable,
whereas its immediate precursor, 18-OHB, is low or normal (Portrat-Doyen et al., 1998).;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the cytochrome P450, subfamily XIB, polypeptide 2 gene (CYP11B2,
124080.0001);
Laboratory abnormalities : Decreased serum aldosterone; Increased serum 18-hydroxycorticosterone (18-OHB); Increased 18-OHB to aldosterone ratio; Increased serum renin; Hyponatremia; Hyperkalemia;
Prefixed ID : #610600;
Origin ID : 610600;
UMLS CUI : C3463917;
Automatic exact mappings (from CISMeF team)
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to NTBT